Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Ruchi M. Newman¶,
Arian Mobascher¶||**,
Ursula Mangold,
Chieko Koike,
Sri Diah,
Marion Schmidt||¶¶,
Daniel Finley||, , and
Bruce R. Zetter||||||
Program in Vascular Biology and Department of Surgery, Children's Hospital, and the ||Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115
Abstract:
Overproduction of the ornithine decarboxylase (ODC) regulatoryprotein ODC-antizyme has been shown to correlate with cell growthinhibition in a variety of different cell types. Although theexact mechanism of this growth inhibition is not known, it hasbeen attributed to the effect of antizyme on polyamine metabolism.Antizyme binds directly to ODC, targeting ODC for ubiquitin-independentdegradation by the 26 S proteasome. We now show that antizymeinduction also leads to degradation of the cell cycle regulatoryprotein cyclin D1. We demonstrate that antizyme is capable ofspecific, noncovalent association with cyclin D1 and that thisinteraction accelerates cyclin D1 degradation in vitro in thepresence of only antizyme, cyclin D1, purified 26 S proteasomes,and ATP. In vivo, antizyme up-regulation induced either by thepolyamine spermine or by antizyme overexpression causes reductionof intracellular cyclin D1 levels. The antizyme-mediated pathwayfor cyclin D1 degradation is independent of the previously characterizedphosphorylation- and ubiquitination-dependent pathway, becauseantizyme up-regulation induces the degradation of a cyclin D1mutant (T286A) that abrogates its ubiquitination. We proposethat antizyme-mediated degradation of cyclin D1 by the proteasomemay provide an explanation for the repression of cell growthfollowing antizyme up-regulation.
Received for publication June 30, 2004.
Revision received July 20, 2004.
* This work was supported by United States Public Health ServiceGrant CA37393 (to B. R. Z.) and by a grant from Aventis (toB. R. Z. and D. F.). The costs of publication of this articlewere defrayed in part by the payment of page charges. This articlemust therefore be hereby marked "advertisement" in accordancewith 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org)contains an additional figure.
Present address: The Burnham Institute, 10901 N. Torrey PinesRd., La Jolla, CA 92037.
¶ These authors contributed equally to this work.
** Present address: Rheinische Kliniken Duesseldorf, Dept. of Psychiatry,Duesseldorf University, Bergische Landstr. 2, 40629 Duesseldorf,Germany. Supported by a fellowship from Dr. Mildred Scheel-Stiftungfuer Krebsforschung.
Genetic Reevaluation of the Role of F-Box Proteins in Cyclin D1 Degradation.
T. Kanie, I. Onoyama, A. Matsumoto, M. Yamada, H. Nakatsumi, Y. Tateishi, S. Yamamura, R. Tsunematsu, M. Matsumoto, and K. I. Nakayama (2012)
Mol. Cell. Biol.
32, 590-605
|Abstract »|Full Text »|PDF »
Evidence of a Role for Antizyme and Antizyme Inhibitor as Regulators of Human Cancer.
Antizyme Affects Cell Proliferation and Viability Solely through Regulating Cellular Polyamines.
Z. Bercovich, Z. Snapir, A. Keren-Paz, and C. Kahana (2011)
J. Biol. Chem.
286, 33778-33783
|Abstract »|Full Text »|PDF »
Parkin Mediates Proteasome-dependent Protein Degradation and Rupture of the Outer Mitochondrial Membrane.
S. R. Yoshii, C. Kishi, N. Ishihara, and N. Mizushima (2011)
J. Biol. Chem.
286, 19630-19640
|Abstract »|Full Text »|PDF »
SLUG-induced Elevation of D1 Cyclin in Breast Cancer Cells through the Inhibition of Its Ubiquitination.
M. K. Mittal, K. Singh, S. Misra, and G. Chaudhuri (2011)
J. Biol. Chem.
286, 469-479
|Abstract »|Full Text »|PDF »
Antizyme Restrains Centrosome Amplification by Regulating the Accumulation of Mps1 at Centrosomes.
C. Kasbek, C.-H. Yang, and H. A. Fisk (2010)
Mol. Biol. Cell
21, 3878-3889
|Abstract »|Full Text »|PDF »
Critical Factors Determining Dimerization of Human Antizyme Inhibitor.
K.-L. Su, Y.-F. Liao, H.-C. Hung, and G.-Y. Liu (2009)
J. Biol. Chem.
284, 26768-26777
|Abstract »|Full Text »|PDF »
Commitment of 1-Methyl-4-phenylpyrinidinium Ion-induced Neuronal Cell Death by Proteasome-mediated Degradation of p35 Cyclin-dependent Kinase 5 Activator.
R. Endo, T. Saito, A. Asada, H. Kawahara, T. Ohshima, and S.-i. Hisanaga (2009)
J. Biol. Chem.
284, 26029-26039
|Abstract »|Full Text »|PDF »
Antizyme is necessary for conversion of pancreatic tumor cells into glucagon-producing differentiated cells.
J.-i. Suzuki, Y. Murakami, K. Samejima, K. K. M. Ohtani, and T. Oka (2009)
Endocr. Relat. Cancer
16, 649-659
|Abstract »|Full Text »|PDF »
PKR and PKR-like Endoplasmic Reticulum Kinase Induce the Proteasome-dependent Degradation of Cyclin D1 via a Mechanism Requiring Eukaryotic Initiation Factor 2{alpha} Phosphorylation.
J. F. Raven, D. Baltzis, S. Wang, Z. Mounir, A. I. Papadakis, H. Q. Gao, and A. E. Koromilas (2008)
J. Biol. Chem.
283, 3097-3108
|Abstract »|Full Text »|PDF »
Association of OAZ1 Gene Polymorphisms With Subclinical and Clinical Vascular Events.
J. Dumont, M. Zureik, C. Bauters, M.-C. Grupposo, D. Cottel, M. Montaye, M. Hamon, P. Ducimetiere, P. Amouyel, and T. Brousseau (2007)
Arterioscler Thromb Vasc Biol
27, 2120-2126
|Abstract »|Full Text »|PDF »
Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression.
E. Nurtjahja-Tjendraputra, D. Fu, J. M. Phang, and D. R. Richardson (2007)
Blood
109, 4045-4054
|Abstract »|Full Text »|PDF »
Ribosomal frameshifting in decoding antizyme mRNAs from yeast and protists to humans: close to 300 cases reveal remarkable diversity despite underlying conservation.
Molecular Basis for the Antiproliferative Effect of Agmatine in Tumor Cells of Colonic, Hepatic, and Neuronal Origin.
C. Wolf, M. Bruss, B. Hanisch, M. Gothert, I. von Kugelgen, and G. J. Molderings (2007)
Mol. Pharmacol.
71, 276-283
|Abstract »|Full Text »|PDF »
Mouse Ornithine Decarboxylase-like Gene Encodes an Antizyme Inhibitor Devoid of Ornithine and Arginine Decarboxylating Activity.
A. J. Lopez-Contreras, C. Lopez-Garcia, C. Jimenez-Cervantes, A. Cremades, and R. Penafiel (2006)
J. Biol. Chem.
281, 30896-30906
|Abstract »|Full Text »|PDF »
Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism.
S. W. Kim, U. Mangold, C. Waghorne, A. Mobascher, L. Shantz, J. Banyard, and B. R. Zetter (2006)
J. Cell Sci.
119, 2583-2591
|Abstract »|Full Text »|PDF »
Tumor suppressor activity of ODC antizyme in MEK-driven skin tumorigenesis.
D. J. Feith, S. Origanti, P. L. Shoop, S. Sass-Kuhn, and L. M. Shantz (2006)
Carcinogenesis
27, 1090-1098
|Abstract »|Full Text »|PDF »
Cell Cycle Perturbations Induced by Infection with the Coronavirus Infectious Bronchitis Virus and Their Effect on Virus Replication.
B. Dove, G. Brooks, K. Bicknell, T. Wurm, and J. A. Hiscox (2006)
J. Virol.
80, 4147-4156
|Abstract »|Full Text »|PDF »
Evolutionary specialization of recoding: Frameshifting in the expression of S. cerevisiae antizyme mRNA is via an atypical antizyme shift site but is still +1.